Linical Co., Ltd.
Notice Regarding Large Order
Linical Co., Ltd. secured a large order worth 20.4 million USD from a U.S. biotech company. The contract delay was caused by partial U.S. government shutdowns and reduced FDA operations; the impact on the fiscal year ending March 2027 has been incorporated into the outlook announced in May 2026.
Key Figures
- Order Amount: 20.4 million USD (3,212 million yen)
- Counterparty: U.S. biotech company
- Timing of Impact: Impact on the fiscal year ending March 2027 has been incorporated into the earnings guidance
AI要約
Overview of the Large Order
This matter concerns a large order from a U.S. biotech company. The cause of the contract delay is attributable to past partial closures of U.S. government agencies and a reduction in FDA operations. Order activity in the U.S. continues to trend upward, and the company intends to proactively pursue further order acquisition. The order amount is 20.4 million USD (3,212 million yen); details are as stated.
Financial Impact and Outlook
It is stated that the impact on results for the fiscal year ending March 2027 has been incorporated into the earnings guidance announced on May 15, 2026. An exchange rate for JPY/USD on the acquisition date is provided as reference, but a detailed breakdown of the impact on financial results is unknown.
Linical Co., Ltd.
Company overview · Stock price · Financial data · All IR
